Exchange Traded Concepts LLC Invests $672,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Exchange Traded Concepts LLC acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 21,559 shares of the specialty pharmaceutical company’s stock, valued at approximately $672,000.

A number of other institutional investors have also made changes to their positions in the business. Commonwealth Equity Services LLC increased its stake in shares of Supernus Pharmaceuticals by 3.6% in the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock worth $273,000 after purchasing an additional 350 shares during the period. Covestor Ltd increased its stake in shares of Supernus Pharmaceuticals by 15.3% in the first quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 358 shares during the period. GAMMA Investing LLC grew its position in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares in the last quarter. Louisiana State Employees Retirement System grew its position in Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock worth $741,000 after buying an additional 600 shares in the last quarter. Finally, Texas Permanent School Fund Corp grew its position in Supernus Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 47,814 shares of the specialty pharmaceutical company’s stock worth $1,631,000 after buying an additional 619 shares in the last quarter.

Analysts Set New Price Targets

SUPN has been the topic of a number of recent research reports. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday.

Supernus Pharmaceuticals Trading Up 2.1 %

NASDAQ SUPN opened at $34.54 on Friday. The stock’s 50 day moving average is $33.03 and its two-hundred day moving average is $30.31. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of 383.78 and a beta of 0.88. Supernus Pharmaceuticals, Inc. has a 1-year low of $21.99 and a 1-year high of $35.44.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). The company had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) earnings per share. On average, analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.